Spero Therapeutics, Inc. (Nasdaq:SPRO)

Health Care/Life Sciences • Biotechnology

CIK 1701108

Company

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Address
675 Massachusetts Avenue
14th floor
Cambridge, Massachusetts 02139

Employees
35

Stock Info

Close
$1.7400

Day Range
1.6600 - 1.7501

52 Week Range
0.9900 - 1.9950

Average volume
205.09K

Short Interest
564K (02/29/24)

% of Float Shorted
1.59%

Market Cap
$87.98M

Revenue
$48.58M

Net Income
-$46.42M

2020 Sales Growth
N/A

Rev. per Employee
$2.036M

P/E Ratio
181.25

EPS
$0.0096

Yield
N/A

Dividend
N/A

Ex-Dividend Date
N/A

Key Executives

Board Of Directors

Chairman
Ankit A Mahadevia MD, MBA

President, Chief Executive Officer & Director
Satyavrat Shukla CFA, MBA

Independent Director
Frank E Thomas CPA

Independent Director
Scott T Jackson MBA

Lead Independent Director
Patrick Volkert Vink MD, MBA

Independent Director
Milind S Deshpande PhD

Independent Director
Kathleen Tregoning

Independent Director
Cynthia Smith MBA

Independent Director
John C Pottage Jr., MD

SEC filings

Date	Form	Event
14 Nov, 2024	8-K
14 Nov, 2024	10-Q
14 Nov, 2024	SC 13G/A
12 Nov, 2024	4
29 Oct, 2024	8-K
10 Sep, 2024	8-K
29 Aug, 2024	4
29 Aug, 2024	4
29 Aug, 2024	4
6 Aug, 2024	4
5 Aug, 2024	10-Q
5 Aug, 2024	S-8
5 Aug, 2024	8-K
3 Jun, 2024	8-K
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
30 May, 2024	4
15 May, 2024	8-K
15 May, 2024	10-Q
16 Apr, 2024	DEFA14A
16 Apr, 2024	ARS
16 Apr, 2024	DEF 14A
29 Mar, 2024	8-K
22 Mar, 2024	EFFECT
20 Mar, 2024	UPLOAD
20 Mar, 2024	CORRESP
15 Mar, 2024	S-8
15 Mar, 2024	S-3
13 Mar, 2024	10-K
13 Mar, 2024	8-K
14 Feb, 2024	SC 13G
9 Feb, 2024	8-K	CEO Change
5 Feb, 2024	4
5 Feb, 2024	4
5 Feb, 2024	4
5 Feb, 2024	4
5 Feb, 2024	4
5 Feb, 2024	4
5 Feb, 2024	144
8 Jan, 2024	8-K
5 Jan, 2024	8-K
4 Jan, 2024	4
2 Jan, 2024	8-K
15 Nov, 2023	3
15 Nov, 2023	4
13 Nov, 2023	S-8
13 Nov, 2023	S-8
13 Nov, 2023	10-Q
13 Nov, 2023	8-K
1 Nov, 2023	8-K
16 Oct, 2023	8-K/A
10 Oct, 2023	4
10 Oct, 2023	8-K
10 Oct, 2023	4
10 Oct, 2023	4
10 Oct, 2023	4
10 Oct, 2023	4
10 Oct, 2023	4
10 Oct, 2023	4
10 Oct, 2023	4
15 Sep, 2023	4
1 Sep, 2023	DEF 14A
1 Sep, 2023	ARS
30 Aug, 2023	4
30 Aug, 2023	4
30 Aug, 2023	4
30 Aug, 2023	4
29 Aug, 2023	144
22 Aug, 2023	PRE 14A
10 Aug, 2023	10-Q
10 Aug, 2023	S-8
10 Aug, 2023	8-K
3 Aug, 2023	4
31 Jul, 2023	8-K
24 Jul, 2023	3
14 Jun, 2023	4
14 Jun, 2023	8-K	CEO Change
11 May, 2023	8-K
11 May, 2023	10-Q
30 Mar, 2023	10-K
30 Mar, 2023	8-K
30 Mar, 2023	S-8
14 Feb, 2023	SC 13G/A
14 Feb, 2023	SC 13G/A
6 Feb, 2023	4
3 Feb, 2023	4
3 Feb, 2023	4
3 Feb, 2023	4
3 Feb, 2023	4
3 Feb, 2023	4
1 Feb, 2023	8-K
20 Jan, 2023	SC 13D/A
19 Jan, 2023	CT ORDER
9 Jan, 2023	8-K
5 Jan, 2023	4
5 Jan, 2023	4
15 Nov, 2022	D
14 Nov, 2022	3
14 Nov, 2022	10-Q
14 Nov, 2022	SC 13D/A
14 Nov, 2022	S-8
14 Nov, 2022	8-K
8 Nov, 2022	8-K
3 Oct, 2022	SC 13G/A
26 Sep, 2022	4
22 Sep, 2022	8-K
19 Sep, 2022	4
19 Sep, 2022	4
19 Sep, 2022	4
19 Sep, 2022	4
19 Sep, 2022	4
19 Sep, 2022	8-K
19 Sep, 2022	4
19 Sep, 2022	4
14 Sep, 2022	3
14 Sep, 2022	4
6 Sep, 2022	8-K
30 Aug, 2022	4
10 Aug, 2022	8-K
10 Aug, 2022	10-Q
5 Aug, 2022	DEFA14A
5 Aug, 2022	DEF 14A
8 Jul, 2022	SC 13G
1 Jul, 2022	8-K
27 Jun, 2022	8-K
7 Jun, 2022	8-K
16 May, 2022	8-K
16 May, 2022	10-Q
3 May, 2022	8-K
28 Apr, 2022	4
7 Apr, 2022	8-K
31 Mar, 2022	10-K
31 Mar, 2022	4
31 Mar, 2022	8-K
16 Mar, 2022	4
9 Mar, 2022	SC 13G/A
2 Mar, 2022	4
23 Feb, 2022	4
16 Feb, 2022	8-K
14 Feb, 2022	SC 13G/A
14 Feb, 2022	SC 13G/A
3 Feb, 2022	4
3 Feb, 2022	4
3 Feb, 2022	4
3 Feb, 2022	SC 13G/A
3 Feb, 2022	4
3 Feb, 2022	4
3 Feb, 2022	4
1 Feb, 2022	4
26 Jan, 2022	4
25 Jan, 2022	8-K
25 Jan, 2022	SC 13G/A
20 Jan, 2022	4
19 Jan, 2022	8-K
12 Jan, 2022	4
7 Jan, 2022	4
7 Jan, 2022	4
7 Jan, 2022	4
4 Jan, 2022	8-K
3 Jan, 2022	4
29 Dec, 2021	4
16 Dec, 2021	CT ORDER
12 Nov, 2021	4
10 Nov, 2021	10-Q
10 Nov, 2021	8-K
2 Nov, 2021	4
28 Oct, 2021	8-K
14 Oct, 2021	3
12 Oct, 2021	8-K
4 Oct, 2021	4
30 Sep, 2021	8-K
20 Sep, 2021	S-8
16 Sep, 2021	SC 13D/A
15 Sep, 2021	4
10 Sep, 2021	4
1 Sep, 2021	4
30 Aug, 2021	4
30 Aug, 2021	4
30 Aug, 2021	8-K
30 Aug, 2021	4
30 Aug, 2021	4
30 Aug, 2021	4
30 Aug, 2021	4
27 Aug, 2021	4
24 Aug, 2021	4
18 Aug, 2021	4
18 Aug, 2021	4
18 Aug, 2021	8-K
18 Aug, 2021	4
18 Aug, 2021	4
18 Aug, 2021	4
18 Aug, 2021	4
18 Aug, 2021	4
5 Aug, 2021	10-Q
5 Aug, 2021	8-K
14 Jul, 2021	D
9 Jul, 2021	SC 13G
6 Jul, 2021	DEF 14A
1 Jul, 2021	8-K
25 Jun, 2021	PRE 14A
6 May, 2021	8-K
6 May, 2021	10-Q
29 Mar, 2021	EFFECT
24 Mar, 2021	CORRESP
23 Mar, 2021	10-K/A
17 Mar, 2021	UPLOAD
11 Mar, 2021	10-K
11 Mar, 2021	S-8
11 Mar, 2021	8-K
11 Mar, 2021	S-3
16 Feb, 2021	SC 13D/A
16 Feb, 2021	SC 13G/A
16 Feb, 2021	SC 13G/A
10 Feb, 2021	SC 13G/A
10 Feb, 2021	4
5 Feb, 2021	8-K
4 Feb, 2021	4
3 Feb, 2021	4
3 Feb, 2021	4
3 Feb, 2021	4
3 Feb, 2021	4
2 Feb, 2021	SC 13G
2 Feb, 2021	SC 13G/A
19 Jan, 2021	8-K
6 Jan, 2021	4
6 Jan, 2021	4
6 Jan, 2021	4
6 Jan, 2021	4
5 Jan, 2021	4
5 Jan, 2021	3

Last update:2024-03-12 12:02:51.163335

Sign Up to Subscribe

Interested in special situations?

Join Tickerverse

customize event filters
create watchlists, bookmarks
get email notifications for the latest special situations
browse and analyze public companies, executives and SEC filings

Tickerverse is a great way to find investment opportunities in corporate actions.

By signing up you agree to our Terms of Service and Privacy Policy.